Open Access

Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer

  • Authors:
    • Cédric Poyet
    • Thomas Hermanns
    • Qing Zhong
    • Eva Drescher
    • Daniel Eberli
    • Maximilian Burger
    • Ferdinand Hofstaedter
    • Arndt Hartmann
    • Robert Stöhr
    • Ellen C. Zwarthoff
    • Tullio Sulser
    • Peter J. Wild
  • View Affiliations

  • Published online on: September 9, 2015     https://doi.org/10.3892/ol.2015.3691
  • Pages: 2753-2760
  • Copyright: © Poyet et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In addition to conventional clinicopathological parameters, molecular markers are also required in order to predict the course of disease in patients with urothelial bladder cancer (BC). Little is known about fibroblast growth factor receptor 3 (FGFR3) immunoreactivity and the clinical significance it may possess with regard to BC. The present study aimed to investigate the immunoreactivity of FGFR3 in primary urothelial bladder tumours, with regard to clinicopathological features and FGFR3 mutation status. Tissue microarrays were used to immunohistochemically analyse FGFR3 expression in 255 primary, unselected patients with BC. FGFR3 mutations were detected using SNaPshot analysis. Positive FGFR3 immunoreactivity was identified in 113/207 analysable cases (54.6%), and was significantly associated with FGFR3 mutation (P<0.001), low tumour stage (P<0.001), low histological grade (P<0.001) and a papillary growth pattern (P<0.001). Positive FGFR3 immunostaining (P=0.002) and FGFR3 mutation (P=0.002) were found to be significantly associated with increased disease‑specific survival following univariate analysis, demonstrating a median follow‑up period of 75 months. Using multivariate analyses, FGFR3 immunoreactivity was found not to be independent of classical pathological parameters. Immunohistochemical expression of FGFR3 is an early occurrence during the carcinogenesis of papillary non‑invasive BC. The presence of FGFR3 immunoreactivity in non‑invasive papillary urothelial carcinomas may be utilised as an indicator of tumours possessing low-grade features and good prognosis.

References

1 

Heney NM: Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am. 19:429–433. 1992.PubMed/NCBI

2 

Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr and Schellhammer PF: Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 178:2314–2330. 2007. View Article : Google Scholar : PubMed/NCBI

3 

Eble J, Sauter G, Epstein JI and Sesterhenn IA: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press. (Lyon). 2004.

4 

Wu XR: Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer. 5:713–725. 2005. View Article : Google Scholar : PubMed/NCBI

5 

Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH, Steyerberg EC, Stoehr R, Kirkels WJ, Denzinger S, Wild PJ, et al: Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: A prospective study. Eur Urol. 54:835–843. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Turner N and Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer. 10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Dieci MVI, Arnedos M, Andre F and Soria JC: Fibroblast growth factor receptor inhibitors as a cancer treatment: From a biologic rationale to medical perspectives. Cancer Discov. 3:264–279. 2013. View Article : Google Scholar : PubMed/NCBI

8 

Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP and Radvanyi F: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 23:18–20. 1999. View Article : Google Scholar : PubMed/NCBI

9 

Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, de Medina S Gil Diez, Van Rhijn B, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC, et al: Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 158:1955–1959. 2001. View Article : Google Scholar : PubMed/NCBI

10 

van Rhijn BW, Montironi R, Zwarthoff EC, Jöbsis AC and van der Kwast TH: Frequent FGFR3 mutations in urothelial papilloma. J Pathol. 198:245–251. 2002. View Article : Google Scholar : PubMed/NCBI

11 

van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boevé ER, Jöbsis AC and Zwarthoff EC: Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 21:1912–1921. 2003. View Article : Google Scholar : PubMed/NCBI

12 

van Oers JM, Wild PJ, Burger M, Denzinger S, Stoehr R, Rosskopf E, Hofstaedter F, Steyerberg EW, Klinkhammer-Schalke M, Zwarthoff EC, et al: FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol. 52:760–768. 2007. View Article : Google Scholar : PubMed/NCBI

13 

Hernández S, López-Knowles E, Lloreta J, Kogevinas M, Jaramillo R, Amorós A, Tardón A, García-Closas R, Serra C, Carrato A, et al: FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis. Clin Cancer Res. 11:5444–5450. 2005. View Article : Google Scholar : PubMed/NCBI

14 

Zieger K, Dyrskjøt L, Wiuf C, Jensen JL, Anderson CL, Jensen KM and Ørntoft TF: Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res. 11:7709–7719. 2005. View Article : Google Scholar : PubMed/NCBI

15 

van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, et al: The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol. 187:310–314. 2012.PubMed/NCBI

16 

van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boevé ER, Jöbsis AC and Zwarthoff EC: FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 64:1911–1914. 2004. View Article : Google Scholar : PubMed/NCBI

17 

Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, et al: FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 63:8108–8112. 2003.PubMed/NCBI

18 

Tomlinson DC, Baldo O, Harnden P and Knowles MA: FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 213:91–98. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Mhawech-Fauceglia P, Cheney RT, Fischer G, Beck A and Herrmann FR: FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol. 32:231–237. 2006. View Article : Google Scholar : PubMed/NCBI

20 

Maeng YH, Eun SY and Huh JS: Expression of fibroblast growth factor receptor 3 in the recurrence of non-muscle-invasive urothelial carcinoma of the bladder. Korean J Urol. 51:94–100. 2010. View Article : Google Scholar : PubMed/NCBI

21 

Gudjónsson S, Bendahl PO, Chebil G, Höglund M, Lindgren D, Lundberg LM, Lövgren K, Fernö M, Månsson W and Liedberg F: Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer? Scand J Urol Nephrol. 45:270–277. 2011. View Article : Google Scholar : PubMed/NCBI

22 

di Martino E, Tomlinson DC and Knowles MA: A decade of FGF receptor research in bladder cancer: Past, present, and future challenges. Adv Urol. 2012:4292132012. View Article : Google Scholar : PubMed/NCBI

23 

Gómez-Román JJ, Saenz P, Molina M, González J Cuevas, Escuredo K, Cruz S Santa, Junquera C, Simón L, Martínez A, Baños JL Gutiérrez, et al: Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res. 11(2 Pt 1): 459–465. 2005.PubMed/NCBI

24 

Poyet C, Jentsch B, Hermanns T, Schweckendiek D, Seifert HH, Schmidtpeter≈ M, Sulser T, Moch H, Wild PJ and Kristiansen G: Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin Pathol. 14:102014. View Article : Google Scholar : PubMed/NCBI

25 

Matsumoto M, Ohtsuki Y, Ochii K, Seike Y, Iseda N, Sasaki T, Okada Y, Kurabayashi A and Furihata M: Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions. Oncol Rep. 12:967–971. 2004.PubMed/NCBI

26 

Bernard-Pierrot I, Brams A, Dunois-Lardé C, Caillault A, de Medina SG Diez, Cappellen D, Graff G, Thiery JP, Chopin D, Ricol D and Radranyi F: Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis. 27:740–747. 2006. View Article : Google Scholar : PubMed/NCBI

27 

Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Requena MJ and Montironi R: Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: The role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol. 122:444–452. 2004. View Article : Google Scholar : PubMed/NCBI

28 

Hernández S, López-Knowles E, Lloreta J, Kogevinas M, Amorós A, Tardón A, Carrato A, Serra C, Malats N and Real FX: Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 24:3664–3671. 2006. View Article : Google Scholar : PubMed/NCBI

29 

Barbisan F, Santinelli A, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, van der Kwast T and Montironi R: Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer. 112:636–644. 2008. View Article : Google Scholar : PubMed/NCBI

30 

van Rhijn BW: Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer. Urol Oncol. 30:518–523. 2012. View Article : Google Scholar : PubMed/NCBI

31 

Bodoor K, Ghabkari A, Jaradat Z, Alkhateeb A, Jaradat S, Al-Ghazo MA, Matalka I, Musleh H and Haddad Y: FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol. 34:724–732. 2010. View Article : Google Scholar : PubMed/NCBI

32 

Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, et al: FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 3:835–844. 2014. View Article : Google Scholar : PubMed/NCBI

33 

Turo R, Harnden P, Thygesen H, Fleischmann A, Thalmann GN, Seiler R, Cross WR and Knowles MA: FGFR3 expression in primary invasive bladder cancers and matched lymph node metastases. J Urol. 193:325–330. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

November 2015
Volume 10 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Poyet, C., Hermanns, T., Zhong, Q., Drescher, E., Eberli, D., Burger, M. ... Wild, P.J. (2015). Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer. Oncology Letters, 10, 2753-2760. https://doi.org/10.3892/ol.2015.3691
MLA
Poyet, C., Hermanns, T., Zhong, Q., Drescher, E., Eberli, D., Burger, M., Hofstaedter, F., Hartmann, A., Stöhr, R., Zwarthoff, E. C., Sulser, T., Wild, P. J."Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer". Oncology Letters 10.5 (2015): 2753-2760.
Chicago
Poyet, C., Hermanns, T., Zhong, Q., Drescher, E., Eberli, D., Burger, M., Hofstaedter, F., Hartmann, A., Stöhr, R., Zwarthoff, E. C., Sulser, T., Wild, P. J."Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer". Oncology Letters 10, no. 5 (2015): 2753-2760. https://doi.org/10.3892/ol.2015.3691